Leerink Partnrs Issues Negative Forecast for Sanofi Earnings

Key Points

• Analysts at Leerink Partners have lowered their Q3 2025 earnings per share estimate for Sanofi to $1.48, down from $1.58, reflecting concerns about the company's financial outlook.
• Sanofi's latest quarterly earnings report showed an earnings miss with $0.90 EPS, falling short of the $0.96 consensus estimate, despite revenues exceeding expectations at $11.34 billion.
• Several brokerages have recently upgraded their ratings for Sanofi, with the stock now holding a consensus rating of "Buy" and an average price target of $62.67, indicating positive sentiment from analysts.

Sanofi (NASDAQ:SNY - Free Report) - Analysts at Leerink Partnrs reduced their Q3 2025 earnings per share estimates for shares of Sanofi in a report released on Tuesday, October 7th. Leerink Partnrs analyst D. Risinger now anticipates that the company will earn $1.48 per share for the quarter, down from their previous estimate of $1.58. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share.

Sanofi (NASDAQ:SNY - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $0.90 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. The business's revenue was down 7.0% on a year-over-year basis. During the same period in the prior year, the company posted $1.73 earnings per share.

A number of other brokerages have also recently weighed in on SNY. Wall Street Zen raised Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Weiss Ratings reissued a "hold (c)" rating on shares of Sanofi in a research note on Wednesday. Morgan Stanley raised Sanofi from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $56.00 to $58.00 in a research note on Monday, September 8th. JPMorgan Chase & Co. raised Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $62.67.

Sanofi Price Performance

Shares of SNY opened at $48.80 on Thursday. The company has a market cap of $119.83 billion, a P/E ratio of 11.73, a PEG ratio of 1.20 and a beta of 0.51. The stock has a fifty day moving average price of $48.18 and a 200 day moving average price of $49.92. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. Sanofi has a 12 month low of $44.62 and a 12 month high of $60.12.

Institutional Trading of Sanofi

Several institutional investors have recently bought and sold shares of SNY. Ameritas Advisory Services LLC bought a new position in Sanofi in the 2nd quarter valued at $28,000. Accent Capital Management LLC bought a new stake in shares of Sanofi during the first quarter worth $29,000. Eastern Bank raised its position in shares of Sanofi by 121.0% during the first quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after acquiring an additional 300 shares during the last quarter. Banque Transatlantique SA bought a new stake in shares of Sanofi during the first quarter worth $33,000. Finally, Golden State Wealth Management LLC raised its position in shares of Sanofi by 619.3% during the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after acquiring an additional 545 shares during the last quarter. Institutional investors and hedge funds own 14.04% of the company's stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.